pyruvic acid has been researched along with th 302 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choudhuri, R; DeGraff, W; Devasahayam, N; Gillies, RJ; Hart, CP; Kesarwala, AH; Kishimoto, S; Krishna, MC; Matsumoto, S; Matsuo, M; Mitchell, JB; Munasinghe, JP; Saito, K; Subramanian, S; Takakusagi, Y; Wojtkowiak, JW | 1 |
1 other study(ies) available for pyruvic acid and th 302
| Article | Year |
|---|---|
Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Humans; Mice; Mitochondria; Nitroimidazoles; Oxygen; Oxygen Consumption; Phosphoramide Mustards; Prodrugs; Pyruvic Acid; Time Factors; Xenograft Model Antitumor Assays | 2014 |